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We present a microfluidic method that uses control of interfacial chemistry in nanoliter droplets
to enable miniaturized in vitro measurements of protein aggregation. Measuring aggregation
of proteins experimentally is fundamental to understanding the biophysics of amyloidosis[1,
2] and for developing methods for detection and treatment of amyloid diseases.[3] In traditional
in vitro aggregation experiments, adsorption of amyloid peptides at the air/water[4] and solid/
water[5,6] interfaces accelerates peptide aggregation by enhancing nucleation. Intrinsic
stochasticity of nucleation phenomena[7] implies that obtaining statistically significant data
often requires multiple experiments performed in parallel, and this makes miniaturization of
these experiments attractive. The interfacial effects, however, become even more pronounced
on miniaturization of aggregation experiments, as miniaturization increases the surface-to-
volume ratio. Miniaturization of aggregation experiments is especially desirable for samples
available only in small volumes, such as cerebrospinal fluid (CSF) from mice. The CSF is
known to contain components that inhibit formation of amyloid aggregates, and the balance
of inhibitory and pro-aggregation activities changes with aging and progression of disease.
[8–10] Therefore, CSF and interstitial brain fluid[11] are increasingly interesting for biomarker
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discovery and monitoring effects of drugs in animal models of Alzheimer’s diseases. Such
panels of experiments are not easily done with standard well-plate in vitro assays that require
tens of microliters of sample, given that the volume of CSF from a single mouse is only a few
microliters. Here we show how such experiments can be performed by using a microfluidic
system.
To miniaturize aggregation experiments while controlling the interfacial chemistry, we used a
plug-based microfluidic approach[12] in polydimethylsiloxane (PDMS)[13] microfluidic
devices modified with teflon tubing.[14] Plugs are nanoliter fluorocarbon-surrounded aqueous
droplets formed in the flow of immiscible fluids inside microfluidic channels. To test this
approach, we used an exceptionally well characterized amyloid beta peptide, namely, Aβ40.
Once Aβ40 is encapsulated inside a plug, it is protected from the surfaces of microchannels by
a layer of fluorocarbon, and the surface chemistry of the aqueous/fluorous interface, rather than
aqueous/channel interface, becomes important. To test whether adsorption of Aβ40 at the
aqueous/fluorous interface can be minimized, we compared the behavior of Aβ40 labeled with
HiLyte-488 at the N terminus at two liquid/liquid interfaces: 1) aqueous peptide/fluorocarbon
interface and 2) aqueous peptide/Rf-OEG3-protected fluorocarbon interface, where Rf-OEG3
is an amphiphilic fluorinated surfactant (see Supporting Information) that is added to the carrier
fluid, assembles spontaneously at the aqueous/fluorous interface, presents triethylene glycol
groups to the aqueous phase, and thereby prevents protein adsorption.[15] In plugs with the
fluorocarbon/water interface, an increase in the fluorescence signal of the labeled Aβ40 peptide
at the plug edges indicated adsorption of the peptide at the interface 2 h after encapsulation
(Figure 1 b). In contrast, in plugs with an Rf-OEG3/water interface, the fluorescence signal of
the labeled peptide was evenly distributed (Figure 1c), that is, Rf-OEG3 prevents Aβ40
adsorption at the interface. The effectiveness of Rf-OEG3 is a function of its concentration in
the carrier fluid (see Supporting Information). Because prior to encapsulation of Aβ40 in plugs,
the peptide is exposed to the walls of the channels, we inserted teflon tubing[14] into the Aβ
inlet. To confirm that Aβ40 was not lost during the encapsulation process, we measured the
fluorescence intensity of a series of plugs protected with Rf-OEG3 containing between 5 and
40 µM fluorescein-labeled Aβ40 after encapsulation. We found a linear increase in intensity that
coincided with the increase of intensity of fluorescein (combined R2 = 0.99), a compound that
is not significantly adsorbed on surfaces in our devices (Figure S1, Supporting Information).
Having established the inertness of the plug/fluorocarbon interface to peptide adsorption, we
monitored the differences in the aggregation kinetics of Aβ40 in plugs with and without Rf-
OEG3 by using Thioflavin T (ThT), a dye widely used to monitor aggregation, and observing
the increase in the fluorescence of ThT on binding to amyloid aggregates.[16] The aggregation
kinetics of Aβ40 depends on nucleation and is typically described by a sigmoidal curve.[1]
First, we measured aggregation kinetics of 50 µM Aβ40 in volumes of 100 µL in well plates,
where we observed a lag period of about 10 h before ThT fluorescence indicated Aβ40
aggregation (Figure 1d). In plugs with the fluorocarbon/water interface, the lag time of the
aggregation reaction shortened to about 2 h (Figure 1e), correlated with the adsorption of the
peptide to the fluorocarbon/water interface and also with the increased surface-to-volume ratio
in 10 nL volumes. In contrast, in plugs with an Rf-OEG3/water interface the lag time of
aggregation increased to many days (Figure 1 f). After 250 h, only 3 plugs out of 15 showed
evidence of Aβ40 aggregation. Even after 2 months, only 8 plugs out of 15 showed evidence
of Aβ40 aggregation (data not shown). Thus, control of the interfacial chemistry decreases the
aggregation kinetics of Aβ40 by at least an order of magnitude.
Next we tested whether this system could reliably handle aggregation experiments with small
volumes by using CSF from a single mouse for a set of experiments. We compared the ability
to inhibit Aβ40 aggregation for CSF (5 µL) from two mouse strains. In this comparison, we
used a nontransgenic (wild-type, wt) mouse and a ceAPPswePS1ΔE9/TTR-/- transgenic mouse
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that exhibits amyloid deposition throughout the cortex and hippocampus.[17] The
ceAPPswePS1ΔE9/TTR-/- mice lack the gene encoding transthyretin (TTR), a molecule that
is enriched in CSF[18] and known to associate with Aβ40 in both in vitro and in vivo settings.
[19,20] The inhibitory potency of CSF for each mouse was tested by generating plugs
containing buffer, ThT, Aβ40, and different volumes of CSF. We described the amount of CSF
in each plug in terms of “volume fraction” (the ratio of the volume of CSF in the plug to the
total aqueous volume of the plug). Titrations were performed by changing the relative flow
rates of all inlet streams[21] to generate plugs containing constant concentrations of ions and
buffer, ThT, and Aβ40, but different volume fractions of CSF (see Supporting Information for
the titration algorithm). For each of the 15 different concentrations of CSF, 50 plugs were
generated, giving 750 experiments for each sample of CSF. Aggregation of Aβ40 was then
monitored by the increase in ThT fluorescence. In contrast to the experiments with low ionic
strength (Figure 1), the ionic strength of the buffer solution in CSF experiments was adjusted
to accelerate aggregation and to resemble the ion composition of mouse CSF, which includes
a high concentration of Ca2+ and Mg2+ ions. In accord with previous reports, the higher ionic
strength led to a decrease in the lag time of aggregation of Aβ40[22] (see also Supporting
Information).
Cerebrospinal fluid from the wild-type mouse was able to inhibit Aβ40 aggregation when added
to plugs at volume fractions higher than 0.04 (Figure 2b). On the other hand, CSF from the
ceAPPswePS1ΔE9/TTR-/- mouse did not inhibit Aβ40 aggregation at volume fractions as high
as 0.2 (Figure 2c). These results agree with the difference in the inhibitory potency of human
CSF from patients with and without Alzheimer’s disease.[23] A qualitatively similar inhibitory
effect on Aβ40 aggregation was observed with recombinant TTR alone in plugs (Figure 2d),
although this effect was substantially weaker. Concentrations of TTR of about 0.2–0.4 µM,
close to the physiological concentration of TTR in CSF,[9] were sufficient to inhibit
aggregation. On the other hand, CSF from a wild-type mouse could be diluted 25-fold (to a
water fraction of 0.04) without detectable loss of inhibitory activity. A dilution of TTR alone
by less than 10- fold (to 50 µM) caused a substantial decrease in its ability to inhibit aggregation.
This result implies that mouse TTR made, and possibly further modified, in vivo is considerably
better at inhibiting aggregation than heterologously expressed human TTR, or it suggests that
other factors in CSF can inhibit aggregation. The microfluidic system described here is
attractive for performing further experiments to identify these putative factors in human CSF.
In conclusion, we used plug-based microfluidics and control of surface chemistry to
miniaturize peptide aggregation experiments to nanoliter volumes. Although here we used the
ThT assay to analyze aggregation in the micromolar range, plug-based microfluidics is
compatible with other analytical methods potentially applicable to analysis in the nanomolar
range, for example, mass spectrometry[24] or fluorescence correlation spectroscopy.[25] This
approach could further advance in vitro aggregation biophysics, for example, time-controlled
aging and nucleation–growth experiments[26] on amyloid peptides. Reducing “extrinsic”
aggregation nucleated and driven by interfaces is attractive for understanding intrinsic
aggregation mechanisms, and for finding molecules added in solution or attached to the
interfaces[27] that can either accelerate or inhibit aggregation. Using plug-based microfluidics,
we demonstrated that in aggregation assays the inhibitory activity of 5 µL of CSF from a single
mouse can be evaluated by setting up hundreds of experiments. In the area of Alzheimer’s
research, we are especially interested in the additional opportunities for evaluating potential
diagnostic methods and for monitoring potential treatments. This approach may enable
repeated analysis of CSF or brain interstitial fluid[11] from the same live animal, for example,
by using the chemistrode.[25]
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Encapsulation and aggregation of Aβ40 in plugs with controlled interfaces compared with plugs
without interfacial control and with a well plate. a) Schematic of the microfluidic device.
Fluorescence images of 22 µM HiLyte-488-labeled Aβ40 in plugs with b) fluorocarbon/water
and c) Rf-OEG3/water interface. Corresponding line scans of the plugs are given below each
image. Aggregation kinetics of 50 µM Aβ40 in 50 µM Tris buffer at 37°C measured by ThT
fluorescence in d) a well plate with an air/water interface, e) plugs with a fluorocarbon/water
interface, and f) plugs with an Rf-OEG3/water interface. Note the difference in timescales.
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CSF titration experiments. a) Microfluidic device designed for performing 250 aggregation
trials of Aβ40 with different volume fractions of CSF or concentrations of protein. Aggregation
kinetics of 50 µM Aβ40 on addition of various volume fractions of CSF b) from wild-type mouse
and c) from a mouse which is a model for Alzheimer’s disease (ceAPPswePS1ΔE9/TTR-/-).
The volume fraction is defined as the ratio of volume of CSF to total aqueous plug volume and
is shown to the right of the graphs. d) Aggregation kinetics of 50 µM Aβ40 on addition of various
concentrations of TTR. Aggregation was measured by ThT fluorescence, where I is the
fluorescence intensity of ThT normalized to the fluorescence intensity at t = 0. Each data point
is averaged over 15 plugs, and the error bars are the standard deviations.
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